



## SPECIAL ARTICLE

# Are *Mycoplasma pneumoniae* coinfections frequent in COVID-19 patients? A systematic review<sup>☆</sup>



Jessica Mosmann<sup>a,\*</sup>,<sup>1</sup>, María Celia Frutos<sup>a,h</sup>,<sup>1</sup>, Javier Anibal Origlia<sup>b</sup>,  
María Lucia Gallo Vaulet<sup>c</sup>, Miriam Gabriela García<sup>d</sup>, Gabriela Vilar<sup>e</sup>,  
Celeste Pérez<sup>e</sup>, María Julia Madariaga<sup>g</sup>, Cecilia Cuffini<sup>a,h</sup>,<sup>2</sup>, María Estela Cadario<sup>e,f</sup>,<sup>2</sup>

<sup>a</sup> Instituto de Virología, Dr. J.M. Vanella, Facultad de Ciencias Médicas – Universidad Nacional de Córdoba, Córdoba, Argentina

<sup>b</sup> Cátedra de Patología de Aves y Pilíferos, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina

<sup>c</sup> Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica, Buenos Aires, Argentina

<sup>d</sup> Laboratorio de Virología y Biología Molecular, Hospital Interzonal General Agudos Pedro Fiorito, Buenos Aires, Argentina

<sup>e</sup> Departamento de Bacteriología, INEI-ANLIS Dr. Carlos G Malbrán, Ciudad Autónoma de Buenos Aires, Argentina

<sup>f</sup> Departamento de Virología, INEI-ANLIS Dr. Carlos G Malbrán, Ciudad Autónoma de Buenos Aires, Argentina

<sup>g</sup> Sección Serología y Pruebas Biológicas, Instituto de Zoonosis Luis Pasteur, Ciudad Autónoma de Buenos Aires, Argentina

<sup>h</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina

Received 30 May 2023; accepted 6 May 2024

Available online 10 July 2024

## KEYWORDS

SARS-CoV-2 infection;  
COVID-19;  
*Mycoplasma pneumoniae*;  
Coinfection

**Abstract** Understanding the proportion of SARS-CoV-2 patients with *Mycoplasma pneumoniae* coinfection is crucial for treating patients suffering from coronavirus disease (COVID-19), help to ensure responsible use of antibiotics and minimize the negative consequences of overuse. In addition, this knowledge could have an impact on empirical antibiotic management guidelines for patients with COVID-19. This systematic review aimed to identify the prevalence of *M. pneumoniae* in patients with coronavirus disease 2019 (COVID-19).

A bibliographic search of studies published in Spanish or English was conducted using the PubMed search engine. Fourteen articles from different continents (America, Asia and Europe) were included, involving a total of 5855 patients in these studies. The mean age of COVID-19 patients with *M. pneumoniae* was 48 years old (range 1–107), most of whom were male. The detection of laboratory-confirmed *M. pneumoniae* infection varied between 0 and 33.3%. Most of patients referred fever, cough, and dyspnea, and received empirical antibiotic treatment. Bacterial coinfection was not associated with increased ICU admission and mortality. The prevalence of coinfection showed extremely dissimilar figures according to the population studied

<sup>☆</sup> Grupo de Trabajo Bacterias Atípicas, Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología.

\* Corresponding author.

E-mail address: [jessica.mosmann@unc.edu.ar](mailto:jessica.mosmann@unc.edu.ar) (J. Mosmann).

<sup>1</sup> These first authors contributed equally to this work.

<sup>2</sup> These authors contributed equally to this work.

and diagnostic criteria. However, it is important to develop Latin American studies, given the heterogeneity observed in the studies conducted in different countries. Standardized definitions should be developed in order to be able to assess the impact of coinfections in patients with a diagnosis of COVID-19.

© 2024 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## PALABRAS CLAVE

Infección por SARS-CoV-2; COVID-19; *Mycoplasma pneumoniae*; Coinfección

## ¿Son frecuentes las coinfecciones con *Mycoplasma pneumoniae* en pacientes con COVID-19? Una revisión sistemática

**Resumen** Comprender la proporción de coinfección por coronavirus (COVID-19) y *Mycoplasma pneumoniae* es crucial para tratar a los pacientes con COVID-19, garantizando el empleo responsable de antibióticos y minimizando las consecuencias negativas del uso excesivo. Además, este conocimiento podría tener un impacto en las pautas de manejo empírico de antibióticos en pacientes con COVID-19. Esta revisión sistemática tuvo como objetivo identificar la prevalencia de *M. pneumoniae* en pacientes con COVID-19. Para ello se realizó una búsqueda bibliográfica de estudios publicados en español o inglés utilizando el buscador PubMed. Se incluyeron 14 artículos de diferentes continentes (América, Asia y Europa), con un total de 5855 pacientes estudiados. La media de edad de los pacientes COVID-19 con *M. pneumoniae* fue de 48 años (intervalo: 1 a 107 años) y la mayoría de ellos fueron varones. La detección de *M. pneumoniae* confirmada por laboratorio en pacientes con COVID-19 varió del 0 al 33,3%. La mayoría de los pacientes refirieron fiebre, tos y disnea, y recibieron antibióticos empíricos. La coinfección bacteriana no se asoció con un aumento de la admisión en UCI ni de la mortalidad. La prevalencia de coinfección fue muy disímil según la población estudiada y los criterios diagnósticos empleados. Dada la heterogeneidad de resultados en los diferentes países, es importante desarrollar estudios en América Latina, como así también establecer definiciones estandarizadas para poder evaluar el impacto real de las coinfecciones en pacientes con COVID-19.

© 2024 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

*Mycoplasma pneumoniae* (*M. pneumoniae*) commonly causes infections of the respiratory system among all age groups<sup>42</sup>. This microorganism is one of the leading causes of community-acquired pneumonia (CAP), especially in children. Most pneumonia cases are benign, whereas some of them may develop into severe pneumonia and refractory pneumonia with pleural effusion, multi-organ dysfunction, and serious long-term sequelae, including bronchiolitis obliterans and bronchiectasis<sup>16</sup>. Airborne droplets containing *M. pneumoniae* can be transmitted and spread among people through coughing and sneezing. In most cases, clinical symptoms are non-specific and cough is the main symptom, which is usually paroxysmal and often persistent<sup>43</sup>. Coinfection of *M. pneumoniae* has been identified in viral pneumonia<sup>40</sup>. At present, coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 virus has spread to almost every part of the world. The combination of SARS-CoV-2 infection and other respiratory pathogens is a challenge for health care systems in terms of diagnosis, treatment, and management. Although viral infection and bacterial infection are essentially different in terms of pathogenesis, the clinical manifestations of COVID-19 and CAP, such as fever, dry cough, fatigue, all-over ache and chest tightness<sup>46</sup>, are similar. Clinical practice indicates that

reactive lymphocytes are frequently observed in COVID-19 infection, while in *M. pneumoniae* infection cold agglutination is common<sup>20</sup>. There are only subtle differences in radiographic features between these two infections<sup>17</sup>.

Several studies have reported a wide range of coinfection rates in SARS-CoV-2 patients, with rates ranging from 3% to more than 20% being reported<sup>24</sup>. Therefore, studies that identify the pathogens coinfecting COVID-19 patients and the evaluation of their impact on the clinical outcome are crucial. These data may guide clinicians to establish a directed antimicrobial therapy, decrease the irrational use of antibiotics and improve the clinical outcome.

The objective was to assess the molecular prevalence of coinfection with this atypical bacterium in COVID-19 patients and describe the clinical features, laboratory parameters, complications, clinical outcomes of such coinfections, to determine the importance of detecting *M. pneumoniae* in patients with COVID 19 and establishing an adequate treatment.

## Materials and methods

A systematic review of the literature was performed focusing on the identification of *M. pneumoniae* coinfections in SARS-CoV-2 patients. PubMed was searched using a combination of key terms such as COVID-19 and *M. pneumoniae*,




Figure 1 PRISMA flow-chart.

SARS-COV-2 and *M. pneumoniae*, bacterial coinfections and COVID-19, pneumonia and SARS-COV-2, pneumonia and COVID-19. We also used the same terms in Spanish and included articles written in English and Spanish (the primary languages of the investigators). We also reviewed the reference lists for the articles identified by our search, as well as those of any included studies. We only included those studies using molecular methods for *M. pneumoniae* detection and excluded all studies employing culture or serology techniques for *M. pneumoniae* identification.

### Data abstraction

Each abstract and the articles selected for full review were evaluated by all investigators. For each included article, the study characteristics and data regarding detection were abstracted by the authors. For detection data, defined cases were included and possible cases were excluded. For each report, the type of surveillance used, number of cases reported and total population studies were documented. This review was conducted and reported according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow-charts (Fig. 1).

### Results and discussion

The literature search yielded 103 studies. After a first screening, 64 were excluded because they were not related to the subject and 4 were duplicate. After full text reading, 14 studies were included (Fig. 1). Specifically, four of the studies were retrospective and ten were prospective. Most

studies were from the USA, Brazil, China and France and the remaining ones from the United Kingdom, Spain, India, Turkey, Peru and Iran. A total of 5855 COVID-19 patients were identified and included in our review (Table 1).

Concerns regarding coinfections during viral pandemics, specifically coinfections with respiratory bacterial pathogens, are borne from the experience in H1N1 influenza A, Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS)<sup>1,22,33</sup>. In these outbreaks, as in the COVID-19 pandemic, much lower coinfection rates with *M. pneumoniae* were reported<sup>5,11,36,39,45</sup>. The prevalence of reported *M. pneumoniae* infections in COVID-19 patients ranged from 0–33.3% in the retrospective studies and 0–28.1% in the prospective studies. These differences in the proportion of coinfection may be attributable to the selection of case-patients (adults or children), geographic factors, season and the clinical condition<sup>9,10,25,27</sup>. High prevalence of coinfection between *M. pneumoniae* and SARS CoV-2 was described using serological methods<sup>18,28,47</sup>. However, these methods are not highly specific tests and may result in an overestimation of infections<sup>37</sup>. In general, the bacterium less frequently found in coinfection with SARS-COV-2 is *M. pneumoniae*<sup>13,15,16</sup>. Many of the most recent studies showed that coinfections appeared to be relatively rare. However, due to the variability between countries and the limited country/region representation in the few studies published, the results shown cannot be extrapolated to Latin America. That is why it is important to generate local evidence to support decision-making. In Argentina, only one multicenter study reported the presence of *M. pneumoniae* in 12.3% (24/187) of COVID-19 patients, using nested-PCR<sup>14</sup>.

**Table 1** Summary of studies reporting the incidence of *M. pneumoniae* co- and secondary infection among COVID-19 patients.

Authors	Country	Type of study	Age <sup>a</sup>	Overall rate of coinfection (%)	<i>M. pneumoniae</i> / SARS-CoV-2 (%)	Diagnostic methods	Treatment	Outcomes of COVID19/ <i>M. pneumoniae</i> patients (%)
Blasco et al., 2020 <sup>2</sup>	Spain	Retrospective	64	3/103 (2.9)	1/3 (33.3)	Multiplex PCR assay	NR	NR
Boschiero et al., 2022 <sup>3</sup>	Brazil	Prospective	NR	84/1503 (5.6)	2/84 (2.38)	RT-PCR (respiratory pathogen panel)	NR	NR
Chaudry et al., 2022 <sup>5</sup>	India	Prospective	50	17/194 (8.7)	3/17 (17.6)	RT-PCR (CARDS toxin gene)	Azithromycin, or fluoro-quinolones, or doxycycline	NR
Chi et al., 2020 <sup>6</sup>	China	Retrospective	53.5	0/17 (0.0)	0/0 (0.0)	Multiplex PCR	NR	NA
Contou et al., 2020 <sup>8</sup>	France	Retrospective	61	26/92 (28.0)	0/26 (0.0)	RT-PCR (respiratory pathogen panel)	NR	NA
Easom et al., 2020 <sup>12</sup>	United Kingdom	Prospective	42.4	29/67 (43.3)	1/67 (1.5)	Multiplex PCR	Doxycycline and monofloxacin	0
Hazra et al., 2020 <sup>19</sup>	USA	Prospective	NR	15/459 (3.0)	0/459 (0.0)	RT-PCR (respiratory pathogen panel)	NR	NA
Husain et al., 2022 <sup>21</sup>	France	Retrospective	69	22/784 (2.8)	2/22 (9.1)	Multiplex PCR	NR	NR
Karaaslan et al., 2021 <sup>23</sup>	Turkey	Retrospective	10	7/93 (7.5)	1/93 (1.07)	PCR	Azithromycin	0
Kim et al., 2020 <sup>24</sup>	USA	Prospective	49	23/115 (20.0)	0/116 (0.0)	RT-PCR (respiratory pathogen panel)	NR	NA
Pérez-Lazo et al., 2021 <sup>30</sup>	Peru	Prospective	58	154/295 (52.2)	83/295 (28.1)	PCR	Azithromycin	15 (18.1) died
Richardson et al. 2020 <sup>34</sup>	USA	Prospective	63	42/1996 (2.1%)	1/42 (2.4)	RT-PCR (respiratory pathogen panel)	NR	NR
Soltani et al., 2021 <sup>38</sup>	Iran	Prospective	52	10/40 (25.0)	9/40 (22.5)	PCR (P1 adhesion gene)	NR	NR
Varela et al., 2022 <sup>41</sup>	Brazil	Prospective	5	31/97 (31.9)	0/31 (0.0)	RT-PCR (respiratory pathogen panel)	Azithromycin	NA

<sup>a</sup> Years (mean). NR: not reported. NA: not applicable. *M. pneumoniae*: *Mycoplasma pneumoniae*.

In two studies (Table 1), most patients who had contracted a bacterial respiratory infection did not test positive for COVID-19<sup>3,4,24</sup>. The median age of COVID-19 patients studied for *M. pneumoniae* was 48 years old (range 1–107), most of whom were male<sup>2,5,8,21,23,30,34,38</sup>. This observation is not consistent with the established literature that indicates that community-acquired viral coinfections are more common in younger populations<sup>35</sup>.

The most common clinical symptoms in COVID-19 coinfecting patients were fever, cough and dyspnea<sup>5,6,12,21,23,30,38</sup>. However, these symptoms are similar among COVID-19 mono-infections and coinfections with other pathogens, which made the clinical differentiation difficult. Thus, laboratory confirmation is required.

The clinical presentations of *M. pneumoniae* range from mild infections affecting the upper respiratory tract to pneumonia that needs hospital admission<sup>43</sup>. It has been proposed that pathogens such as *M. pneumoniae* can exacerbate clinical symptoms, increase morbidity and prolong the stay in the intensive care unit (ICU) in COVID-19 patients<sup>5,13,23,30,34</sup>. Boschiero et al., 2022<sup>3</sup> did not find an association between coinfections and more severe COVID-19-related outcomes in Brazil, while Perez-Lazo et al., 2021<sup>30</sup> reported a high rate of mortality in Peru (18.1%). The authors described an elevated development of sepsis in the group with *M. pneumoniae* coinfections (37.4%); however, they found that mortality was similar among coinfecting and mono-infected groups<sup>30</sup>. In two studies included in this review a lower mortality rate was found<sup>12,23</sup>, whereas the remaining studies did not report any mortality rates<sup>2,3,5,21,34,38</sup>. Lower rates of comorbidities, such as hypertension, diabetes mellitus, renal disease and obesity<sup>5,30</sup> were described in coinfecting patients.

Antibiotic use was reported in five studies<sup>5,12,23,30,41</sup>, with >50% of patients receiving empirical antibiotics<sup>30</sup>. This is particularly important in Latin America, where the abuse of antibiotics in COVID-19 patients has reached alarming levels<sup>7,32</sup>. The finding that there was a low number of patients with bacterial infections, such as *M. pneumoniae*, *Klebsiella pneumoniae*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, highlights the fact that the empirical use of antibiotics in patients with COVID-19 should not be recommended<sup>26,29,31,44</sup>. The COVID-19 pandemic exacerbated the known challenges to optimal antibiotic administration, representing a direct threat to patient safety and public health through antibiotic overprescription and promotion of bacterial resistance.

Unfortunately, there were no specific data on clinical information and therapeutic interventions. Due to the diversity of studies and the low number of patients with detected coinfection with *M. pneumoniae*, it was difficult to find symptoms indicating coinfection with *M. pneumoniae* and SARS-CoV-2 in the studies included in our review.

Despite the fact that *M. pneumoniae* coinfections were searched and infrequently documented in patients with COVID-19 pneumonia, routine testing for respiratory pathogens should be advised, since agents for which specific therapy can be prescribed may be detected and may have a beneficial impact on patient outcomes.

## Ethical approval

Not required.

## Funding

None.

## Conflict of interests

The authors declare that they have no conflicts of interest.

## References

1. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, Shalhoub S, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Al Mekhlafi GA, Al Harthy A, Kharaba A, Ahmadi MA, Sadat M, Mutairi HA, Qasim EA, Jose J, Nasim M, Al-Dawood A, Merson L, Fowler R, Hayden FG, Balkhy HH, Saudi Critical Care Trial Group. Critically ill patients with the middle East respiratory syndrome: a multicenter retrospective cohort study. *Crit Care Med.* 2017;45:1683–95.
2. Blasco ML, Buesa J, Colomina J, Forner MJ, Galindo MJ, Navarro J, Noceda J, Redón J, Signes-Costa J, Navarro D. Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia. *J Med Virol.* 2020;92:1799–801.
3. Boschiero MN, Duarte A, Palamim CVC, Alvarez AE, Mauch RM, Marson FAL. Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing. *Diagn Microbiol Infect Dis.* 2022;102:115576.
4. Calcagno A, Ghisetti V, Burdino E, Trunfio M, Allice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. *Clin Microbiol Infect.* 2021;27:297–8.
5. Chaudhry R, Sreenath K, Batra P, Vinayaraj EV, Rathor N, Saikiran K, Aravindan A, Singh V, Brijwal M, Soneja M, Verma N, Subramaniam R, Singh UB, Guleria R. Atypical bacterial coinfections among patients with COVID-19: a study from India. *J Med Virol.* 2022;94:303–9.
6. Chi Q, Dai X, Jiang X, Zhu L, Du J, Chen Y, Zheng J, Huang J. Differential diagnosis for suspected cases of coronavirus disease 2019: a retrospective study. *BMC Infect Dis.* 2020;20:679.
7. Chiara Chilet CM, Saavedra Velasco M. Control de antibióticos en tiempos de COVID-19 ¿verdad o mito? *Rev Fac Med Humana.* 2020;20.
8. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, Cally R, Logre E, Fraissé M, Mentec H, Plantefève G. Bacterial and viral coinfections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive Care.* 2020;10:119.
9. Cox MJ, Loman N, Bogaert D, O'Grady J. Coinfections: potentially lethal and unexplored in COVID-19. *Lancet Microbe.* 2020;1:e11.
10. Davis B, Rothrock AN, Swetland S, Andris H, Davis P, Rothrock SG. Viral and atypical respiratory coinfections in COVID-19: a systematic review and meta-analysis. *J Am Coll Emerg Physicians Open.* 2020;1:533–48.
11. Dhanoa A, Fang NC, Hassan SS, Kaniappan P, Rajasekaram G. Epidemiology and clinical characteristics of hospitalized patients with pandemic influenza A (H1N1) 2009 infections: the effects of bacterial coinfection. *Virol J.* 2011;8:501.
12. Easom N, Moss P, Barlow G, Samson A, Taynton T, Adams K, Ivan M, Burns P, Gajee K, Eastick K, Lillie PJ. Sixty-eight consecutive patients assessed for COVID-19 infection: experience from a UK Regional infectious diseases Unit. *Influenza Other Respir Viruses.* 2020;14:374–9.
13. Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong KH, Kuperan P. COVID-19 and *Mycoplasma pneumoniae* coinfection. *Am J Hematol.* 2020;95:723–4.

14. Favier P, Piñeiro F, Serio E, Damico N, De Izarbe M, Pinilla F, Muñoz C, Arteaga A, Kumar L, Prismot I, Gallino I, Pérez J, Raffo C, Carrillo J, Hermida L, Luna C, Padilla M, Montiel G, Ripoll P, Kovac A, Andreani M, Gorbaran V, Rodríguez O, Guelfand L, Abusamra L, Sisto A, Prieto M, Vilar G, Lara C, Motter A, Nusblat L, Moncalero S, Rolón MJ, Cadario ME. Prevalence of atypical pathogens in SARS-CoV 2 coinfection in Argentina: finding what we were not looking for. 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). July 2021.
15. Gao LW, Yin J, Hu YH, Liu XY, Feng XL, He JX, Liu J, Guo Y, Xu BP, Shen KL. The epidemiology of paediatric *Mycoplasma pneumoniae* pneumonia in North China: 2006–2016. *Epidemiol Infect.* 2019;147:e192.
16. Gao ZA, Gao LB, Chen XJ, Xu Y. Forty-nine years old woman coinfecting with SARS-CoV-2 and *Mycoplasma*: a case report. *World J Clin Cases.* 2020;8:6080–5.
17. Gayam V, Konala VM, Naramala S, Garlapati PR, Merghani MA, Regmi N, Balla M, Adapa S. Presenting characteristics, comorbidities, and outcomes of patients coinfecting with COVID-19 and *Mycoplasma pneumoniae* in the USA. *J Med Virol.* 2020;92:2181–7.
18. Guarino M, Perna B, Cuoghi F, Spampinato MD, Cesaro AE, Manza F, Pretula A, Grilli A, Maritati M, Caio G, Carnevale A, Flacco ME, De Giorgio R, Contini C. Role of intracellular pulmonary pathogens during SARS-CoV-2 infection in the first pandemic wave of COVID-19: clinical and prognostic significance in a case series of 1200 patients. *Microorganisms.* 2022;10:1636.
19. Hazra A, Collison M, Pisano J, Kumar M, Oehler C, Ridgway JP. Coinfections with SARS-CoV-2 and other respiratory pathogens. *Infect Control Hosp Epidemiol.* 2020;41:1228–9.
20. Huang AC, Huang CG, Yang CT, Hu HC. Concomitant infection with COVID-19 and *Mycoplasma pneumoniae*. *Biomed J.* 2020;43:458–61.
21. Husain M, Valayer S, Poey N, Rondinaud E, d’Humières C, Visseaux B, Lariven S, Lescure FX, Deconinck L. Pulmonary bacterial infections in adult patients hospitalized for COVID-19 in standard wards. *Infect Dis Now.* 2022;52:208–13.
22. Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. *J Infect.* 2004;48:23–31.
23. Karaastan A, Çetin C, Akin Y, Demir Tekol S, Söbü E, Demirhan R. Coinfection in SARS-CoV-2 infected children patients. *J Infect Dev Ctries.* 2021;15:761–5.
24. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of coinfection between SARS-CoV-2 and other respiratory pathogens. *JAMA.* 2020;323:2085–6.
25. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JPR, Daneman N. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect.* 2020;26:1622–9.
26. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, MacFadden DR. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect.* 2021;27:520–1.
27. Lansbury L, Lim B, Baskaran V, Lim WS. Coinfections in people with COVID-19: a systematic review and meta-analysis. *J Infect.* 2020;81:266–75.
28. Li Y, Wang H, Wang F, Lu X, Du H, Xu J, Han F, Zhang L, Zhang M. Coinfections of SARS-CoV-2 with multiple common respiratory pathogens in infected children: a retrospective study. *Medicine (Baltimore).* 2021;100:e24315.
29. Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, Nyatigo F, Cook CA, Hinterwirth A, Lebas E, Redd T, Porco TC, Lietman TM, Arnold BF, Doan T. Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial. *JAMA.* 2021;326:490–8.
30. Pérez-Lazo G, Silva-Caso W, Del Valle-Mendoza J, Morales-Moreno A, Ballena-López J, Soto-Febres F, Martins-Luna J, Carrillo-Ng H, Del Valle LJ, Kym S, Aguilar-Luis MA, Peña-Tuesta I, Tinco-Valdez C, Illescas LR. Identification of coinfections by viral and bacterial pathogens in COVID-19 hospitalized patients in Peru: molecular diagnosis and clinical characteristics. *Antibiotics (Basel).* 2021;10:1358.
31. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet.* 2021;397:1063–74.
32. Pulia MS, Wolf I, Schulz LT, Pop-Vicas A, Schwei RJ, Lindenauer PK. COVID-19: an emerging threat to antibiotic stewardship in the emergency department. *West J Emerg Med.* 2020;21:1283–6.
33. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR 3rd, Higgs E, Randolph AG, Smoot BE, Thompson BT, NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. *Crit Care Med.* 2012;40:1487–98.
34. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajjizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *J Am Med Assoc.* 2020;323:2052–9.
35. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. *Lancet.* 2011;377:1264–75.
36. Sangil A, Calbo E, Robles A, Benet S, Viladot ME, Pascual V, Cuchí E, Pérez J, Barreiro B, Sánchez B, Torres J, Canales L, De Marcos JA, Garau J. Aetiology of community-acquired pneumonia among adults in an H1N1 pandemic year: the role of respiratory viruses. *Eur J Clin Microbiol Infect Dis.* 2012;31:2765–72.
37. Sobieszczkańska BM, Kasprzykowska U, Duda-Madej A, Secewicz A, Marciniak J, Gościński G. Relevance of serology for *Mycoplasma pneumoniae* infection among children with persistent cough. *Adv Clin Exp Med.* 2014;23:185–90.
38. Soltani S, Zandi M, Fani M, Elhami S, Zakeri A, Pakzad R, Abbasi S. *Mycoplasma pneumoniae* and *Legionella pneumophila* coinfection with SARS-CoV-2 infections in COVID-19 patients living in Abadan, Iran. *Afr J Respir Med.* 2021;16:1–4.
39. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, Wong PC, Lam B, Ip MS, Chan J, Yuen KY, Lai KN. A cluster of cases of severe acute respiratory syndrome in Hong Kong. *N Engl J Med.* 2003;348:1977–85.
40. To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, Yuen KY. Avian influenza A H5N1 virus: a continuous threat to humans. *Emerg Microbes Infect.* 2012;1:e25.
41. Varela FH, Sartor ITS, Polese-Bonatto M, Azevedo TR, Kern LB, Fazolo T, de David CN, Zavaglia GO, Fernandes IR, Krauser JRM, Stein RT, Scotta MC. Rhinovirus as the main co-circulating virus during the COVID-19 pandemic in children. *J Pediatr (Rio J).* 2022;98:579–86.
42. Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev.* 2004;17:697–728.
43. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. *Mycoplasma pneumoniae* from the respiratory tract and beyond. *Clin Microbiol Rev.* 2017;30:747–809.
44. Wang L, Amin AK, Khanna P, Aali A, McGregor A, Bassett P, Gopal Rao G. An observational cohort study of bacterial coinfection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. *J Antimicrob Chemother.* 2021;76:796–803.
45. Zahariadis G, Gooley TA, Ryall P, Hutchinson C, Latchford MI, Fearon MA, Jamieson FB, Richardson S, Kuschak T, Mederski

- B. Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacteria coinfection based on diagnostic assays. *Can Respir J.* 2006;13:17–22.
46. Zha L, Shen J, Tefsen B, Wang Y, Lu W, Xu Q. Clinical features and outcomes of adult COVID-19 patients coinfecting with *Mycoplasma pneumoniae*. *J Infect.* 2020;81:12–5.
47. Xing Q, Li G, Xing Y, Chen T, Li W, Ni W, Deng K, Gao R, Chen C, Gao Y, Li Q, Yu G, Tong J, Li W, Hao G, Sun Y, Zhang A, Wu Q, Li Z, Pan S. Precautions are needed for COVID19 patients with coinfection of common respiratory pathogens. *MedRxiv Prepr.* 2020, <http://dx.doi.org/10.1101/2020.02.29.20027698>.